Identification

Generic Name
Fursultiamine
DrugBank Accession Number
DB08966
Background

Compound used for therapy of thiamine deficiency. It has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 398.543
Monoisotopic: 398.144632098
Chemical Formula
C17H26N4O3S2
Synonyms
  • Fursultiamina
  • Fursultiamine
  • Fursultiaminum
  • Thiamin tetrahydrofurfuryl disulfide
  • Thiamine tetrahydrofurfuryl disulfide
  • TTFD

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Fursultiamine hydrochlorideT3557LWB272105-43-3OPGOLNDOMSBSCW-CLNHMMGSSA-N
International/Other Brands
Adventan / Alinamin F / Diteftin / Judolor / Linamin
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ALINAMIN EX PLUSFursultiamine hydrochloride (36.39 MG) + Cyanocobalamin (500 MCG) + Calcium pantothenate (10 MG) + Pyridoxine hydrochloride (33.33 MG) + Vitamin E (33.33 MG)Tablet, sugar coatedOralบริษัท ทาเคดา (ประเทศไทย) จำกัด2014-04-02Not applicableThailand flag
ALINAMIN-F ODORLESS TABLETFursultiamine (50 mg) + Riboflavin (5 mg)Tablet, sugar coatedOralLUEN WAH MEDICAL COMPANY (SINGAPORE) PRIVATE LIMITED1991-06-21Not applicable
Aronamin GoldFursultiamine (50 mg/1) + Ascorbic acid (70 mg/1) + Hydroxocobalamin acetate (5.22 ug/1) + Riboflavin tetrabutyrate (2.5 mg/1) + alpha-Tocopherol acetate (20 mg/1)Tablet, film coatedOralOASIS TRADING2018-11-20Not applicableUS flag
NEVRAMIN TABLETFursultiamine (50 mg) + Cyanocobalamin (250 mcg) + Pyridoxine hydrochloride (250 mg)Tablet, sugar coatedOralLUEN WAH MEDICAL COMPANY (SINGAPORE) PRIVATE LIMITED1991-06-21Not applicable
Nevramin TabletsFursultiamine (50 mg) + Cyanocobalamin (250 mg) + Pyridoxine hydrochloride (250 mg)TabletOralLUEN WAH MEDICAL CO. SDN. BHD.2020-09-08Not applicableMalaysia flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Aronamin GoldFursultiamine (50 mg/1) + Ascorbic acid (70 mg/1) + Hydroxocobalamin acetate (5.22 ug/1) + Riboflavin tetrabutyrate (2.5 mg/1) + alpha-Tocopherol acetate (20 mg/1)Tablet, film coatedOralOASIS TRADING2018-11-20Not applicableUS flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as hydropyrimidines. These are compounds containing a hydrogenated pyrimidine ring (i.e. containing less than the maximum number of double bonds.).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Hydropyrimidines
Alternative Parents
Imidolactams / Tetrahydrofurans / Tertiary carboxylic acid amides / Heteroaromatic compounds / Organic disulfides / Sulfenyl compounds / Oxacyclic compounds / Dialkyl ethers / Azacyclic compounds / Primary alcohols
show 5 more
Substituents
Alcohol / Aromatic heteromonocyclic compound / Azacycle / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Dialkyl ether / Ether / Heteroaromatic compound / Hydrocarbon derivative
show 15 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
05J61265PX
CAS number
804-30-8
InChI Key
JTLXCMOFVBXEKD-FOWTUZBSSA-N
InChI
InChI=1S/C17H26N4O3S2/c1-12(16(5-6-22)26-25-10-15-4-3-7-24-15)21(11-23)9-14-8-19-13(2)20-17(14)18/h8,11,15,22H,3-7,9-10H2,1-2H3,(H2,18,19,20)/b16-12+
IUPAC Name
N-[(4-amino-2-methylpyrimidin-5-yl)methyl]-N-[(2E)-5-hydroxy-3-{[(oxolan-2-yl)methyl]disulfanyl}pent-2-en-2-yl]formamide
SMILES
C\C(N(CC1=C(N)N=C(C)N=C1)C=O)=C(\CCO)SSCC1CCCO1

References

Synthesis Reference

U.S. Patent 3,016,380.

General References
  1. Kobayashi T, Notoya K, Nakamura A, Akimoto K: Fursultiamine, a vitamin B1 derivative, enhances chondroprotective effects of glucosamine hydrochloride and chondroitin sulfate in rabbit experimental osteoarthritis. Inflamm Res. 2005 Jun;54(6):249-55. [Article]
PubChem Compound
3002119
PubChem Substance
310264929
ChemSpider
2273321
RxNav
4604
ChEBI
135636
ChEMBL
CHEMBL1740659
Wikipedia
Fursultiamine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedSupportive CareEczema; Contact, Allergic1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, sugar coatedOral
Tablet, sugar coatedOral50 mg
Tablet, film coatedOral
Injection
Tablet, sugar coatedOral250 mcg
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)132U.S. Patent 3,016,380.
Predicted Properties
PropertyValueSource
Water Solubility0.123 mg/mLALOGPS
logP1.38ALOGPS
logP-0.47Chemaxon
logS-3.5ALOGPS
pKa (Strongest Acidic)15.9Chemaxon
pKa (Strongest Basic)6.26Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area101.57 Å2Chemaxon
Rotatable Bond Count9Chemaxon
Refractivity111.54 m3·mol-1Chemaxon
Polarizability42.81 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at June 09, 2014 15:23 / Updated at February 21, 2021 18:52